Crohn's Disease - Drug Pipeline Analysis and Market Forecasts to 2015

Introduction

GlobalData, the industry analysis specialist’s new report, “Crohn’s Disease – Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global Crohn’s disease market. The report identifies the key trends shaping and driving the global Crohn’s disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Crohn’s disease sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global Crohn’s disease market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes TNF-alpha inhibitor, IL-12 and 23 inhibitor, IL-6 inhibitor, IL-17 inhibitor, chemokine receptor inhibitor, Co stimulation modulator, Anti CD3 molecules, Anti MAP agent, Cell adhesion molecule inhibitor, Oral adsorbents, Other immunosupressors, Stem cell therapy.
- Analysis of the current and future market competition in the global Crohn’s disease market. Key market players covered are Chemocentryx Inc., Bristol-Myers Squibb, Abbott laboratories and Johnson & Johnson.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with Crohn’s disease.

Highlights

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Crohn’s disease market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Crohn’s disease market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Crohn’s disease market landscape? – Identify, understand and capitalize.

Report Highlights
Astrazeneca, Promethus Laboratories , Abbott laboratories , Elan Pharmaceuticals Inc, Biogen Idec, Centocor Ortho Biotech Inc., Johnson & Johnson, Schering-Plough , UCB Pharma, Giaconda limited , Prague clinical services, ChemoCentryx Inc., GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Medimmune, Janssen-cilag
[Studien Infos ausblenden]

Table of Contents

1 Crohn’s Disease Market: Executive Summary
1.1 The Crohn’s Disease Market is Forecast to Show Modest Growth until 2015
1.2 Competition in Crohn’s Disease Market Becoming More Intense
1.3 Current Treatment Options are Moderately Successful in Meeting the Market Demand
1.4 Emerging Therapies in Pipeline are Expected to Increase the Competition
2 Table Of Contents
2.1 List of Tables
2.2 List of Figures
3 Crohn’s Disease Market: Market Characterization
3.1 Overview
3.2 Crohn’s Disease Market Size
3.3 Crohn’s Disease Market Forecast and CAGR
3.4 Drivers and Barriers for the Crohn’s Disease Market
3.4.1 Drivers for the Crohn’s Disease Market
3.4.2 Barriers for the Crohn’s Disease Market
3.5 Opportunity and Unmet Need
3.6 Key Takeaway
4 Crohn’s Disease Market: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Crohn’s Disease Market
4.3.1 Entocort EC (budenoside)
4.3.1.1 Overview
4.3.1.2 Efficacy
4.3.1.3 Safety
4.3.1.4 Pricing
4.3.1.5 Clinical Study Details
4.3.2 Humira (adalimumab)
4.3.2.1 Overview
4.3.2.2 Efficacy
4.3.2.3 Safety
4.3.2.4 Pricing
4.3.2.5 Clinical Study Details
4.3.3 Tysabri (natalizumab)
4.3.3.1 Overview
4.3.3.2 Efficacy
4.3.3.3 Safety
4.3.3.4 Pricing
4.3.3.5 Clinical Study Details
4.3.4 Remicade (infliximab)
4.3.4.1 Overview
4.3.4.2 Efficacy
4.3.4.3 Safety
4.3.4.4 Pricing
4.3.4.5 Clinical Study Details
4.3.5 Cimzia (cetrolizumab pegol)
4.3.5.1 Overview
4.3.5.2 Efficacy
4.3.5.3 Safety
4.3.5.4 Pricing
4.3.5.5 Clinical Study Details
4.4 Key Takeaway
5 Crohn’s Disease Market: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Technology Trends Analytic Framework
5.3 Crohn’s Disease Therapeutics – Promising Drugs under Clinical Development
5.4 Molecule Profile for Promising Drugs under Clinical Development
5.4.1 Myoconda
5.4.1.1 Overview
5.4.1.2 Efficacy
5.4.1.3 Safety
5.4.1.4 Clinical Study Details
5.4.2 Traficet-EN (CCX282)
5.4.2.1 Overview
5.4.2.2 Efficacy
5.4.2.3 Safety
5.4.2.4 Clinical Study Details
5.4.3 MLN0002 (vedolizumab)
5.4.3.1 Overview
5.4.3.2 Efficacy
5.4.3.3 Safety
5.4.3.4 Clinical Study Details
5.4.4 Orencia (abatacept)
5.4.4.1 Overview
5.4.4.2 Efficacy
5.4.4.3 Safety
5.4.4.4 Clinical Study Details
5.4.5 ABT-874
5.4.5.1 Overview
5.4.5.2 Efficacy
5.4.5.3 Safety
5.4.5.4 Clinical Study Details
5.4.6 Stelara
5.4.6.1 Overview
5.4.6.2 Efficacy
5.4.6.3 Safety
5.4.6.4 Clinical Study Details
5.5 Crohn’s Disease Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.6 Crohn’s Disease Pipeline – Pipeline by Clinical Phases of Development
5.6.1 Crohn’s Disease Therapeutics – Phase III Clinical Pipeline
5.6.2 Crohn’s Disease Therapeutics – Phase II Clinical Pipeline
5.6.3 Crohn’s Disease Therapeutics – Phase I Clinical Pipeline
5.6.4 Crohn’s Disease Therapeutics – Preclinical Pipeline
5.6.5 Crohn’s Disease Therapeutics – Discovery Pipeline
5.7 Discontinued / Suspended Drug for Crohn’s Disease
5.8 Key Takeaway
6 Crohn’s Disease Market: Implications for Future Market Competition
7 Crohn’s Disease Market: Future Players in the Crohn’s Disease Market
7.1 Introduction
7.2 ChemoCentryx Inc.
7.2.1 Overview
7.2.2 Autoimmune and Gastrointestinal Disease Portfolio
7.2.2.1 Marketed Products
7.2.2.2 Pipeline Products
7.2.3 Crohn’s Disease Product Portfolio
7.2.3.1 Traficet-EN
7.3 Bristol-Myers Squibb
7.3.1 Overview
7.3.2 Autoimmune and Gastrointestinal Disease Portfolio
7.3.2.1 Marketed Products
7.3.2.2 Pipeline Products
7.3.3 Crohn’s Disease Product Portfolio
7.3.3.1 Orencia
7.4 Abbott Laboratories
7.4.1 Overview
7.4.2 Autoimmune and Gastrointestinal Disease Portfolio
7.4.2.1 Marketed Products
7.4.2.2 Pipeline Products
7.4.3 Crohn’s Disease Product Portfolio
7.4.3.1 ABT-874
7.5 Johnson & Johnson
7.5.1 Overview
7.5.2 Autoimmune and Gastrointestinal Disease Portfolio
7.5.2.1 Marketed Products
7.5.2.2 Pipeline Products
7.5.3 Crohn’s Disease Product Portfolio
7.5.3.1 Stelara
8 Crohn’s Disease Market: Appendix
8.1 Definitions
8.2 Acronyms
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.3.1 Epidemiology-based Forecasting
8.3.4 Primary Research
8.3.5 Expert Panel Validation
8.4 Contact Us
8.5 Disclaimer
8.6 Sources
[Inhaltsverzeichnis ausblenden]

List of Tables

Table 1: Global Crohn’s Disease Therapeutics Market, Revenue Forecasts, 2000–2015
Table 2: Major Marketed Products Comparison in the Crohn’s Disease Market, 2009
Table 3: Crohn’s Disease Therapeutics – Most Promising Drugs Under Clinical Development, 2009
Table 4: Crohn’s Disease Therapeutics – Phase III Clinical Pipeline, 2009
Table 5: Crohn’s Disease Therapeutics – Phase II Clinical Pipeline, 2009
Table 6: Crohn’s Disease Therapeutics – Phase I Clinical Pipeline, 2009
Table 7: Crohn’s Disease Therapeutics – Preclinical Pipeline, 2009
Table 8: Crohn’s Disease Therapeutics – Discovery Pipeline, 2009
Table 9: List of Discontinued Drugs for Crohn’s Disease, 2009
Table 10: ChemoCentryx Inc. – Autoimmune and Gastrointestinal Disease Pipeline Products, 2009
Table 11: Bristol-Myers Squibb – Autoimmune and Gastrointestinal Marketed Products, 2009
Table 12: Bristol-Myers Squibb – Autoimmune and Gastrointestinal Pipeline Products, 2009
Table 13: Abbott Laboratories – Autoimmune and Gastrointestinal Marketed Products, 2009
Table 14: Abbott Laboratories – Autoimmune and Gastrointestinal Pipeline Products, 2009
Table 15: Johnson & Johnson – Autoimmune and Gastrointestinal Marketed Products, 2009
Table 16: Johnson & Johnson – Autoimmune and Gastrointestinal Pipeline Products, 2009
List of Figures

Figure 1: Global Crohn’s Disease Market Forecast 2000–2015
Figure 2: Opportunity and Unmet Need in the Crohn’s Disease Market, 2009
Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Crohn’s Disease, 2009
Figure 4: Technology Trends Analytic Framework of the Crohn’s Disease Pipeline, 2009
Figure 5: Technology Trends Analytic Framework of the Crohn’s Disease Pipeline – Description, 2009
Figure 6: Crohn’s Disease Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2009
Figure 7: Crohn’s Disease Pipeline by Phase of Clinical Development, 2009
Figure 8: Implications for Future Market Competition in the Crohn’s Disease Market, 2009
Figure 9: Crohn’s Disease Therapeutics Market – Clinical Pipeline by Company, 2009
Figure 10: GlobalData Methodology
Figure 11: GlobalData Market Forecasting Model
[Tabellenverzeichnis ausblenden]